Mabwell (Shanghai) Bioscience (SHA:688062, HKG:2493) obtained clinical trial approval for 9MW5211 injection from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.
Shanghai-listed shares of the drug company saw a nearly 3% decrease by Wednesday afternoon, with Hong Kong shares falling 4%.
The drug will be tested for the treatment of Type 1 diabetes mellitus.